Please check your internet connection and try again.
# TAF-Voihep (Tenofovir Alafenamide and Vemlidy - formulation not specified)
## Overview
TAF-Voihep appears to be a combination product containing tenofovir alafenamide (TAF). Vemlidy is a brand name for tenofovir disoproxil fumarate (TDF). The exact formulation and intended use of "TAF-Voihep" are unclear from the provided drug name. This response will focus on TAF as a component, assuming it is used for its antiviral properties.
## Primary Indications
Tenofovir alafenamide (TAF) is approved for:
* Treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients.
* Part of combination therapy for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients.
## Adult Dosing
The typical dose for TAF in chronic HBV infection is **25 mg orally once daily**.
When used as part of HIV-1 combination therapy, the typical dose of TAF is **25 mg orally once daily**.
## Pediatric Dosing
For chronic HBV infection, TAF is approved for pediatric patients aged 12 years and older, and weighing at least 35 kg, at a dose of **25 mg orally once daily**.
For HIV-1 infection, TAF is approved for pediatric patients weighing at least 25 kg, at a dose of **25 mg orally once daily**.
## Dose Adjustments
No dose adjustment is typically required for TAF based on renal impairment unless CrCl is < 15 mL/min (or pediatric patients with CrCl < 30 mL/min) or if the patient is on stable dialysis. In these cases, the dose may need adjustment or discontinuation, consult specific guidelines. Dose adjustments are not usually necessary for hepatic impairment.
## Contraindications
* Hypersensitivity to tenofovir alafenamide or any component of the formulation.
## Adverse Effects
Common adverse effects include:
* Nausea
* Diarrhea
* Headache
* Dizziness
* Fatigue
* Rash
Less common but serious adverse effects may include:
* Lactic acidosis
* Severe hepatomegaly with steatosis
* New or worsening renal impairment, including acute renal failure and Fanconi syndrome
* Decreases in bone mineral density
## Key Drug Interactions
* **Strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat):** May increase tenofovir alafenamide concentrations.
* **Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort):** May decrease tenofovir alafenamide concentrations.
* **Didanosine:** Coadministration with TAF may increase didanosine AUC and may warrant a dose reduction of didanosine.
* **Hepatitis C antivirals:** Interactions can occur, consult specific hepatitis C treatment guidelines.
## Monitoring
* Renal function (serum creatinine, urinalysis for proteinuria and glucosuria) at baseline and periodically during treatment.
* Liver function tests (ALT, AST, bilirubin) at baseline and periodically during treatment, especially in patients with pre-existing hepatic disease.
* Hepatitis B viral load and serological markers (HBsAg, anti-HBs) for chronic HBV.
* HIV viral load and CD4 count for HIV-1.
* Bone mineral density may be considered, especially in patients with a history of fractures or other risk factors.
## Clinical Pearls
* TAF has a lower risk of renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF) due to more efficient delivery of tenofovir to target cells and lower plasma concentrations.
* TAF should be taken with food to improve absorption.
* Discontinuation of TAF in patients with HBV may lead to severe exacerbation of hepatitis.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information or your institution's formulary for complete drug information, including indications, contraindications, warnings, precautions, adverse reactions, and drug interactions. Verify dosing and administration details with local protocols and patient-specific factors.
